Why the study?
Does a high-titer or low-titer quadrivalent rotavirus vaccine improve immunogenicity with acceptable reactogenicity compared to placebo in infants?
Population
302 infants starting at the second month of age in Caracas, Venezuela
Comparison
Three doses of quadrivalent rotavirus vaccine at… vs Placebo (n=102)
Design
RCT, double-masked
Follow-up
4 weeks after the third dose
Authors
Loading...
Lower-titer quadrivalent rotavirus vaccine suffices for immunogenicity; supports its selection for future efficacy trials.
Does a high-titer or low-titer quadrivalent rotavirus vaccine improve immunogenicity with acceptable reactogenicity compared to placebo in infants?
A high-titer quadrivalent rotavirus vaccine offered no immunogenic advantage over a lower-titer preparation, supporting the use of the lower titer in future efficacy trials.
Flores et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: